Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

By T. Bongartz, A. Sutton, M. Sweeting, Iain E. Buchan, E. Matteson, Victor M. Montori. Journal of the American Medical Association (JAMA), 2006

2,568 citations recorded by the source corpus.

Subfields: Hematology, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/7939fbe6f6c025d54b71b5a967dd1907fa99374d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. M. Lebwohl

In Immunology

1. Y. Bae
2. Heiko Blaser
3. Hyunjin Oh
4. D. Brenner
5. Young Do Yoo
6. S. Rhee
7. T. Mak
8. M. Lebwohl

In Rheumatology

1. Martina Anzaghe
2. Yen-Ju Lin
3. D. Tracey
4. Lars Klareskog
5. J. Salfeld
6. P. Tak
7. S. Schülke
8. E. Sasso

Citations in the corpus

• Regulation of tumour necrosis factor signalling: live or let die (2015, background): “As TNF-mediated signalling is very important for many physiological functions in the body, it should not be surprising that the use of TNF-specific and TNFR-specific therapeutics sometimes cause adverse events, including the development of lymphomas and infections 151,152 .”
• Hidradenitis suppurativa: a comprehensive review. (2009, background): “However, a metaanalysis of nine placebo-controlled trials using etanercept or adalimumab in patients with rheumatoid arthritis demonstrated significantly increased malignancies in those receiving high doses ofmedication (6mg/kg of infliximabevery 8weeks or 40 mg of adalimumab every other week) than ”
• A review of stimuli-responsive nanocarriers for drug and gene delivery. (2008, methodology): “One of the FDA approved targeted therapeutics is Adalimumab® antibody; a human antiTNF IgG1 used against rheumatoid arthritis is generated by phage display technique [33].”
• Regulation of reactive oxygen species generation in cell signaling (2011, background): “Since these agents bind to TNF-α or TNF-R to inhibit the physiological function, they may elicit unwanted outcomes including lymphoma development and infection (Bongartz et al., 2006).”
• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “(2006). Development of antiinfliximab antibodies and”
• Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (2008, result): “These findings contrast with the results of a meta-analysis of rheumatoid arthritis studies examining patients treated with adalimumab and infliximab, which revealed an increased risk of solid cancers.(171)”
• Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis (2020, background): “In addition, usage of biological DMARDs may result in elevated levels of transaminases, induction or reactivation of autoimmune conditions such as multiple sclerosis and psoriasis, as well as worsening congestive heart failure [129,287,288].”